Puma Biotechnology | Passivo Circulante





Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Esperion Therapeutics USD 359.03M 60.24M 2025-09
Exelixis USD 405.64M 31.86M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Glaxosmithkline GBP 28.68B 8.3B 2025-09
Incyte USD 1.52B 176.44M 2025-12
MacroGenics USD 44.47M 5.47M 2025-09
Moderna USD 1.99B 306M 2025-12
Novartis USD 32B 286M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Takeda JPY 2.61T 470.53B 2025-12
TG Therapeutics USD 153.76M 3.05M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


Puma Biotechnology Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.